Merge
Get twice-weekly insights on the biggest stories shaping cardiology.
You might also like
Structural Heart May 14, 2026
The Young TAVR Trend is Stabilizing May 14, 2026
Despite a TAVR popularity surge in recent years, a Vizient registry analysis suggests the procedure’s prevalence has stabilized in patients under 65, but there’s still significant debate on whether the young patient TAVR rate is appropriate.
Cardiovascular Disease May 11, 2026
BP Lowering Still Decreases CVD Risk Even in CKD May 11, 2026
Data from a new Lancet study suggests that patients with chronic kidney disease (CKD) might get similar cardiovascular protection from blood pressure drugs as the general population, giving physicians some certainty about how to approach BP in these patients.
Cardiology Pharmaceuticals May 7, 2026
Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug May 7, 2026
The question of how to treat non-obstructive hypertrophic cardiomyopathy has long perplexed researchers and pharmaceutical developers alike, but topline results from Cytokinetics’ Phase 3 ACACIA-HCM trial suggest MYQORZO (aficamten) could be the answer.